- Home
- CSTL
as 03-31-2025 10:34am EST
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME, among others. The company's test portfolio consists of test offerings to aid clinicians in the diagnosis and treatment of cancers or precancerous diagnoses in the fields of dermatology, gastroenterology, and ophthalmology and a pharmacogenomics ("PGx") test to guide optimal drug treatment for patients diagnosed with depression, anxiety, and other mental health conditions.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FRIENDSWOOD |
| Market Cap: | 576.3M | IPO Year: | 2019 |
| Target Price: | $40.00 | AVG Volume (30 days): | 445.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.97 - $35.84 | Next Earning Date: | 05-01-2025 |
| Revenue: | $332,069,000 | Revenue Growth: | 51.09% |
| Revenue Growth (this year): | -11.89% | Revenue Growth (next year): | 6.01% |
Stock Insider Trading Activity of Castle Biosciences Inc. (CSTL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Mar 26 '25 | Sell | $20.30 | 5,644 | $114,573.20 | 65,025 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Mar 4 '25 | Sell | $20.86 | 5,687 | $118,619.45 | 65,025 | |
| Stokes Frank | CSTL | Chief Financial Officer | Feb 20 '25 | Sell | $26.70 | 8,046 | $214,828.20 | 35,319 | |
| BRADBURY DANIEL | CSTL | Director | Feb 5 '25 | Sell | $28.17 | 7,867 | $221,636.99 | 0 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Jan 13 '25 | Sell | $28.55 | 2,565 | $71,902.93 | 65,025 | |
| BRADBURY DANIEL | CSTL | Director | Jan 6 '25 | Sell | $29.21 | 7,867 | $229,225.91 | 0 | |
| Juvenal Tobin W | CSTL | Chief Commercial Officer | Jan 6 '25 | Sell | $30.00 | 2,230 | $66,900.00 | 69,943 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Jan 6 '25 | Sell | $29.47 | 7,689 | $228,066.82 | 65,025 |
Latest Castle Biosciences Inc. News
CSTL Breaking Stock News: Dive into CSTL Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups
Business Wire
24 days ago
New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio
Simply Wall St.
25 days ago
Solid Earnings Reflect Castle Biosciences' (NASDAQ:CSTL) Strength As A Business
Simply Wall St.
a month ago
What Is Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Doing?
Thomson Reuters StreetEvents
a month ago
Q4 2024 Castle Biosciences Inc Earnings Call
GuruFocus.com
a month ago
Castle Biosciences Inc (CSTL) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...
Zacks
a month ago
Castle Biosciences, Inc. (CSTL) Surpasses Q4 Earnings and Revenue Estimates
Business Wire
a month ago
Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results
Compare CSTL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CSTL Castle Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.